EMA Marketing Authorization of New Drugs in April 2025

Shots: The EMA’s CHMP has granted positive opinions and approvals to 4 Biologics and 4 New Chemical Entites in April 2025, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were Amgen’s Tepezza to Treat Thyroid Eye Disease PharmaShots has compiled a list of 8 drugs that have been granted positive opinions…

ByDipanshu DixitMay 20, 2025

INSIGHTS+

PharmaShots’ Key Highlights of First Quarter 2025

Shots:  Q1’2025 highlights major acquisitions in the pharma and biotech industry along with clinical trial results and approvals. The talk of the town remained Intra-Cellular Therapies’ acquisition by Johnson & Johnson for ~$14.6B The quarter highlighted breakthrough results, pivotal clinical data, including Eli Lilly and Incyte's P-III Study Data of Baricitinib to treat Alopecia Areata PharmaShots brings…

ByRidhi RastogiApril 1, 2025

INSIGHTS+

EMA Marketing Authorization of New Drugs in February 2025

Shots: The EMA’s CHMP has granted positive opinions and approvals to 5 Biologics and 2 New Chemical Entities in February 2025, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were Merck’s Welireg to treat Von Hippel-Lindau & Renal Cell Carcinoma PharmaShots has compiled a list of 6 drugs…

ByDipanshu DixitMarch 18, 2025

INSIGHTS+

EMA Marketing Authorization of New Drugs in January 2025

Shots: The EMA’s CHMP has granted positive opinions to 5 Biologics in January 2025, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were Merck’s Capvaxive to treat Pneumococcal Disease PharmaShots has compiled a list of 4 drugs that have been granted positive opinions and approvals by the EMA’s…

ByDipanshu DixitFebruary 18, 2025

INSIGHTS+

EMA Marketing Authorization of New Drugs in December 2024

Shots: The EMA’s CHMP has granted positive opinions to 5 Biologics and 4 New Chemical Entities in December 2024, leading to treatments for patients and advances in the healthcare industry The major highlighted drugs were Galderma’s Nemluvio to treat Prurigo Nodularis and Atopic Dermatitis PharmaShots has compiled a list of 9 drugs that have been granted positive…

ByDipanshu DixitJanuary 23, 2025

INSIGHTS+

Insights+: The US FDA New Drug Approvals in March 2024

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of March 2024 The US FDA approved a total of 14 drugs including 12 new molecular entities and 2 biologics leading to the treatments for patients and advances in the healthcare industry The major highlighted drug was BeiGene’s Tevimbra for treating Advanced…

ByDipanshu DixitApril 15, 2024

INSIGHTS+

Top Performing Drug – Invega Trinza (March Edition) 

Shots:   In continuation to our previous series on the Top-Performing Drug of the month, based on 2021 revenue, this month we have selected Invega Trinza and prepared an engaging analysis for our readers Invega Trinza (3-Months injection) is an atypical antipsychotic drug used for the treatment of schizophrenia in patients after adequately being treated with…

BySenior EditorMarch 19, 2024

INSIGHTS+

Insights+: The US FDA New Drug Approvals in February 2024

Shots: PharmaShots has compiled a list of US FDA-approved drugs in the month of February 2024 The US FDA approved a total of 7 drugs including 6 new molecular entities and 1 biologic leading to the treatments for patients and advances in the healthcare industry The major highlighted drug was Takeda’s Eohilia (budesonide oral suspension) for treating eosinophilic…

BySenior EditorMarch 13, 2024

INSIGHTS+

A Complete Account of EMA Approvals in 2023

Shots: In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology For…

BySenior EditorMarch 5, 2024

INSIGHTS+

A Complete Account of FDA Approvals in 2023

Shots: 2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023 PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology  For the complete report with analysis, reach out to us…

BySenior EditorFebruary 1, 2024

EMA Marketing Authorization of New Drugs in April 2025

PharmaShots’ Key Highlights of First Quarter 2025

EMA Marketing Authorization of New Drugs in February 2025

EMA Marketing Authorization of New Drugs in January 2025

EMA Marketing Authorization of New Drugs in December 2024

Insights+: The US FDA New Drug Approvals in March 2024

Top Performing Drug – Invega Trinza (March Edition)

Insights+: The US FDA New Drug Approvals in February 2024

A Complete Account of EMA Approvals in 2023

A Complete Account of FDA Approvals in 2023

Contact US

OUR INFORMATION

FOLLW US

FOLLW US

Sign Up to Our Newsletter